Atlas Trials

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD

Clinical trial NCT02298283 · COMPLETED

Trial details

NCT number
NCT02298283
Sponsor
The Lymphoma Academic Research Organisation
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Hodgkin Lymphoma
Start date
2015-04-01
Primary completion
2020-07-09
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.